Activated FGFR4 mutants phosphorylate FRS2

Stable Identifier
R-HSA-5655284
Type
Reaction [transition]
Species
Homo sapiens
Compartment
plasma membrane, cytosol
ReviewStatus
5/5
Locations in the PathwayBrowser
Expand all
General
SVG | 
PNG
Low
Medium
High
 | PPTX  | SBGN
Activated FGFR4 mutants phosphorylate FRS2
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
After recruitment to activated FGFR mutants, FRS2 is believed to be phosphorylated, potentially on all 6 of the tyrosines phosphorylated by wild-type FGFRs. Phosphorylation of FRS2 by FGFR has been demonstrated in some cases (see for instance Qing, 2009; Bai, 2010; Ahmed, 2008; Raffioni, 1998) and is inferred to occur in others based on activation of downstream signaling modules (reviewed in Wesche, 2011; Turner and Grose, 2010).
Literature References
PubMed ID Title Journal Year
17505008 AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor

Takeda, M, Arao, T, Yokote, H, Komatsu, T, Yanagihara, K, Sasaki, H, Yamada, Y, Tamura, T, Fukuoka, K, Kimura, H, Saijo, N, Nishio, K

Clin Cancer Res 2007
9857065 Effect of transmembrane and kinase domain mutations on fibroblast growth factor receptor 3 chimera signaling in PC12 cells. A model for the control of receptor tyrosine kinase activation

Raffioni, S, Zhu, YZ, Bradshaw, RA, Thompson, LM

J Biol Chem 1998
18373495 Extracellular point mutations in FGFR2 elicit unexpected changes in intracellular signalling

Ahmed, Z, Schüller, AC, Suhling, K, Tregidgo, C, Ladbury, JE

Biochem J 2008
19381019 Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice

Qing, J, Du, X, Chen, Y, Chan, P, Li, H, Wu, P, Marsters, S, Stawicki, S, Tien, J, Totpal, K, Ross, S, Stinson, S, Dornan, D, French, D, Wang, QR, Stephan, JP, Wu, Y, Wiesmann, C, Ashkenazi, A

J Clin Invest 2009
21711248 Fibroblast growth factors and their receptors in cancer

Wesche, J, Haglund, K, Haugsten, EM

Biochem J 2011
20094046 Fibroblast growth factor signalling: from development to cancer

Turner, N, Grose, RP

Nat Rev Cancer 2010
20709759 GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling

Bai, A, Meetze, K, Vo, NY, Kollipara, S, Mazsa, EK, Winston, WM, Weiler, S, Poling, LL, Chen, T, Ismail, NS, Jiang, J, Lerner, L, Gyuris, J, Weng, Z

Cancer Res 2010
21666749 Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer

Dutt, A, Ramos, AH, Hammerman, PS, Mermel, C, Cho, J, Sharifnia, T, Chande, A, Tanaka, KE, Stransky, N, Greulich, H, Gray, NS, Meyerson, M

PLoS One 2011
Participants
Input
Output
Participates
as an event of
Catalyst Activity

protein tyrosine kinase activity of Activated FGFR4 mutants:FRS2 [plasma membrane]

Physical Entity
Activated FGFR4 mutants:FRS2 [plasma membrane] (Homo sapiens)
Activity
protein tyrosine kinase activity (GO:0004713)
Normal reaction
Activated FGFR4 phosphorylates FRS2 (Homo sapiens)
Functional status

Gain of function of Activated FGFR4 mutants:FRS2 [plasma membrane]

Normal Entity
Disease Entity
Status
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
bone development disease DOID:0080006
Cross References
Mondo
Authored
Rothfels, K  (2012-02-10)
Reviewed
Ezzat, S  (2012-05-15)
Created
Rothfels, K  (2014-12-05)
Cite Us!